AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Adverum Biotechnologies to Present New Preclinical Data on ADVM-022 Gene Therapy for Wet AMD at ASGCT and ARVO

April 16, 2019

MENLO PARK, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of new preclinical data at upcoming conferences, including the American Society of Gene and Cell Therapy (ASGCT) and the Association for Research in Vision and Ophthalmology (ARVO).

“We are pleased to be sharing these new preclinical non-human primate data that add to the growing body of evidence demonstrating ADVM-022 gene therapy’s long-term durability and safety,” said Mehdi Gasmi, Ph.D., president and chief scientific officer of Adverum Biotechnologies. “In an oral presentation at ASGCT, we will be presenting preclinical data to support that a single injection of 2x10^12 vg of ADVM-022 provides durable expression of aflibercept with no deleterious effects on retina structure and function observed out to 30 months. At ARVO, our poster presentation will include preclinical data characterizing immunological response following sequential intravitreal administration of AAV2.7m8 gene therapy and its degree of effect on transduction in the contralateral eye.”

Event: ASGCT 22nd Annual MeetingOral Presentation: Ocular safety of long-term suppression of VEGF by intravitreally-administered gene therapy, ADVM-022, in non-human primatesAbstract Number: 931Session Title: Neurosensory DiseasesDate: May 2, 2019Time: 10:45 – 11:00 am ETLocation: Washington Hilton, Jefferson Room, Washington, D.C.Speaker: Szilard Kiss, M.D., director of clinical research in the Department of Ophthalmology at Weill Cornell Medical College

Panel Presentation: Manufacturing Challenges during Late Phase Development of Gene Therapy ProductsDate: April 28, 2019Time: 3:00 – 4:30 pm ETLocation: Washington Hilton, Jefferson West, Washington, D.C.Participant: Pratik Jaluria, Ph.D., executive director, process development and manufacturing

Event: ARVO 2019 Annual MeetingPoster Presentation: Immunological response and durability of expression following sequential intravitreal administration of AAV2.7m8 gene therapy to the contralateral eye in non-human primatesPoster Board Number: A0097Session Title: Gene Therapy and DeliveryDate: Tuesday, April 30, 2019 Time: 8:45 – 10:30 am PTLocation: West Exhibition Hall, Vancouver Convention Center, Vancouver, BC

About Adverum Biotechnologies, Inc.Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. As a leader in ophthalmic gene therapy, Adverum has collaboration agreements with Regeneron Pharmaceuticals and Editas Medicine. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. For more information, please visit www.adverum.com.

Forward-looking StatementsStatements contained in this press release regarding results or events that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding ADVM-022 potential to demonstrate long-term durability and safety. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that Adverum’s resources will not be sufficient for Adverum to conduct or continue planned development programs and planned clinical trials, and the risk of a delay in the enrollment of patients in Adverum’s clinical studies or in the manufacturing of products to be used in such clinical studies. Risks and uncertainties facing Adverum are described more fully in Adverum’s periodic reports filed with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Adverum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor and Media Inquiries: Amy Figueroa, CFA Investor Relations Consultant afigueroa@adverum.com 650-823-2704